LIXT
Lixte Biotechnology Holdings Inc
NASDAQ: LIXT · HEALTHCARE · BIOTECHNOLOGY
$3.50
+0.00% today
Updated 2026-04-30
Market cap
$44.15M
P/E ratio
—
P/S ratio
20.35x
EPS (TTM)
$-1.26
Dividend yield
—
52W range
$1 – $6
Volume
0.0M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-1.09M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-6.31M | $-5.09M | $-3.59M | $-6.01M | $-2.54M |
| EPS | — | — | — | — | $-1.26 |
| Free cash flow | $-4.61M | $-4.29M | $-3.16M | $-3.07M | $-1.09M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Lixte Biotechnology Holdings Inc trades at $3.50. Our Smart Value Score of 16/100 indicates the stock is weak.
Frequently asked questions
What is Lixte Biotechnology Holdings Inc's stock price?
Lixte Biotechnology Holdings Inc (LIXT) trades at $3.50.
Is Lixte Biotechnology Holdings Inc overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell).
What is the price target of Lixte Biotechnology Holdings Inc (LIXT)?
The analyst target price is $—, representing NaN% downside from the current price of $3.50.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio20.35x
ROE-102.00%
Beta0.95
50D MA$3.04
200D MA$3.90
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—